

**REMARKS**

Applicants thank the Examiner Sean Mc Garry for his time and consideration in the telephone interview of December 2, 2008. The deletion of claims 22, 38, 43 and 48 as requested by the Examiner and addition of new claims now presented were discussed, as well as Applicants disclosure of new information relevant to the instant Application. The Examiner agreed to enter and consider the amendments and an IDS Statement by Supplementary Amendment.

Claims 21-23, 25-27, and 31-54 are pending in the present application. By virtue of this response, claims 22, 38, 43 and 48 have been canceled and new claims 55-58 have been added. Accordingly, claims 21, 23, 25-27, 31-37, 39-42, 44-47 and 49-58 are under consideration upon entry of this amendment. Amendments and cancellation of certain claims is not to be construed as a dedication to the public of any of the subject matter of the claims as previously presented. Applicants reserve the right to pursue prosecution of any presently excluded claim embodiments in future continuation and/or divisional applications.

Support for new claims 55-58 can be found throughout the specification, for example at [0192] of the specification. Applicants respectfully submit that SEQ ID NO: 8 is 100% complementary to SEQ ID NO: 5, which is identical to SEQ ID NO: 15.

The undersigned has been advised that Figure 10B of the Application is included in material that is the subject of an investigation conducted by the Memorial Sloan Kettering Cancer Center, the findings of which have been submitted to the Office of Research Integrity and that are part of an investigation that is in progress by this organization, and that a final determination of the investigation has not yet been made. In an effort to provide full disclosure and comply with any requirements under 37 CFR 1.56, 1.97 and/or 1.98 Applicants provide this information in a Supplemental IDS submitted herewith. Applicants submit and underscore that controls of the nature as depicted in the figure have been run at other times. The data and scientific assertion underlying the figure have been reviewed and repeated with commensurate

result and outcome. In addition, the publication Zhang et al (2008) Cancer Biology and Therapy 7(9): 1492-1497 entitled "Downregulation of KSR in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake", submitted herewith on the enclosed Supplemental IDS, provides correlative and supportive data to Figure 10B and further demonstrates the inhibition of expression of KSR in the presence of antisense oligonucleotide.


**FEES**

No additional fees are believed to be necessitated by the foregoing Response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

**CONCLUSION**

Applicants respectfully request entry of the foregoing amendments and remarks in the file history of the instant application. The claims as amended and presented are believed to be in condition for allowance, and reconsideration and withdrawal of all of the outstanding rejections is therefore believed in order. Early and favorable action on the claims is earnestly solicited. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

Respectfully submitted,



Christine E. Dietzel, Ph.D.  
Agent for Applicant(s)  
Registration No. 37,309

KLAUBER & JACKSON, LLC  
411 Hackensack Avenue  
Hackensack NJ 07601  
Tel: (201) 487-5800